Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Genprex Inc GNPX

Healthcare Biotechnology
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GNPX)

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

PR Newswire 1 day ago

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

PR Newswire November 5, 2024

Genprex to Participate in 2024 BIO Europe Conference

PR Newswire October 31, 2024

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

PR Newswire October 28, 2024

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

PR Newswire October 24, 2024

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

PR Newswire October 15, 2024

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

PR Newswire October 10, 2024

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

PR Newswire October 7, 2024

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

PR Newswire September 23, 2024
View More News ››

Opinion & Analysis (NDAQ:GNPX)

Genprex Shares Soar 250% on FDA Fast Track Designation for Lung Cancer Drug

Streetwise Reports January 22, 2020
View More Opinion ››

Bullboard Posts (NDAQ:GNPX)

Genprex to Participate in 2024 BIO Europe Conference

NEWS: $GNPX Genprex to Participate in 2024 BIO Europe ConferenceGenprex to Participate in 2024 BIO Europe Conference PR Newswire AUSTIN,...
whytestocks - October 31, 2024

Genprex Collaborators Present Positive Preclinical Data on t

JUST IN: $GNPX Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa&#xAE; Gene Therapy for the Treatment of...
whytestocks - October 28, 2024

Genprex Receives Safety Review Committee Approval to Advance

Just In: $GNPX Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3...
whytestocks - October 15, 2024

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene T

Breaking News: $GNPX Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and DiabetesGenprex Featured in CEO...
whytestocks - September 23, 2024

Genprex Announces Formation of Mesothelioma Clinical Advisor

Breaking News: $GNPX Genprex Announces Formation of Mesothelioma Clinical Advisory BoardGenprex Announces Formation of Mesothelioma...
whytestocks - September 19, 2024

$GNPX News!

$GNPX @genprex Genprex Inc Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors https://www.genprex...
MasterJedijazz - May 13, 2024
View more Bullboard ››

Theralase Technologies Inc.

Theralase Technologies Inc.

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research ...
View More »